Verastem Oncology

📍 Needham, United States🗓 Founded 2010👥 73 employees💰 Last funded Apr 2020
Biotechnology Research🌐 verastem.com
Website LinkedIn
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com. Twitter: @VerastemOncolog
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Verastem Oncology?
Verastem Oncology has 1 investors on record on gritt.io and 1 late-stage investors.
When did Verastem Oncology last raise funding?
The most recent investment in Verastem Oncology recorded on gritt.io was in April 2020.
When was Verastem Oncology founded?
Verastem Oncology was founded in 2010.
What industry is Verastem Oncology in?
Verastem Oncology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Verastem Oncology based?
Verastem Oncology is headquartered in Needham, United States.